We are developing APi2568 [clinical-grade MVF-PD-1(92-110)], the drug substance in the drug product IMU-201 administered IM as PD1-Vaxx, to treat cancers that overexpress programmed cell death ligand 1 (PD-L1), such as non-small cell lung cancer (NSCLC), melanoma, renal cancer, and colorectal cancer. This evidence concerns the gene CD274 and renal carcinoma.